At the time of writing, CRISPR Therapeutics AG [CRSP] stock is trading at $42.09, up 0.55%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CRSP shares have gain 13.91% over the last week, with a monthly amount glided 16.46%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
CRISPR Therapeutics AG [NASDAQ: CRSP] stock has seen the most recent analyst activity on February 14, 2025, when Evercore ISI upgraded its rating to a Outperform and also boosted its price target to $99 from $60. Previously, TD Cowen upgraded its rating to Hold on February 12, 2025, and kept the price target unchanged to $35. On February 03, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $65 on the stock. Needham reiterated its Buy rating and decreased its price target to $84 on August 06, 2024. Rodman & Renshaw initiated its recommendation with a Buy and recommended $90 as its price target on August 02, 2024. In a note dated February 15, 2024, Wolfe Research initiated an Peer Perform rating.
For the past year, the stock price of CRISPR Therapeutics AG fluctuated between $30.04 and $67.88. Currently, Wall Street analysts expect the stock to reach $65 within the next 12 months. CRISPR Therapeutics AG [NASDAQ: CRSP] shares were valued at $42.09 at the most recent close of the market. An investor can expect a potential return of 54.43% based on the average CRSP price forecast.
Analyzing the CRSP fundamentals
According to CRISPR Therapeutics AG [NASDAQ:CRSP], the company’s sales were 37.67M for trailing twelve months, which represents an 71.63% jump. Gross Profit Margin for this corporation currently stands at -2.59% with Operating Profit Margin at -13.13%, Pretax Profit Margin comes in at -10.57%, and Net Profit Margin reading is -10.68%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.2 and Total Capital is -0.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 40.85 points at the first support level, and at 39.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 43.53, and for the 2nd resistance point, it is at 44.97.
Ratios To Look Out For
It is important to note that CRISPR Therapeutics AG [NASDAQ:CRSP] has a current ratio of 15.64. Also, the Quick Ratio is 15.64, while the Cash Ratio stands at 1.97. Considering the valuation of this stock, the price to sales ratio is 96.50, the price to book ratio is 1.99.
Transactions by insiders
Recent insider trading involved Patel Naimish, Chief Medical Officer, that happened on May 29 ’25 when 3932.0 shares were sold. Chief Executive Officer, Kulkarni Samarth completed a deal on Mar 21 ’25 to sell 10031.0 shares. Meanwhile, Chief Operating Officer Bruno Julianne sold 1714.0 shares on Mar 21 ’25.
